A Phase IIa Exploratory Study of OCZ103-OS in Combination with Platinum-Gemcitabine based Doublet First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients
Phase of Trial: Phase II
Latest Information Update: 27 Oct 2014
At a glance
- Drugs Pentamidine (Primary) ; Gemcitabine; Platinum complexes
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- Sponsors Oncozyme Pharma
- 28 Jun 2013 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
- 01 May 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01844791).
- 01 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov: US National Institutes of Health.